Phase 1 Study of HS-10541 as Monotherapy or in Combination With Other Anti-cancer Therapies in Patients With KRAS G12C Mutation Advanced Solid Tumors.

This is a multicenter, open-label phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of HS-10541 as monotherapy or in combination with other anti-cancer therapies in participants with KRAS G12C mutation advanced solid tumors.

NCT Number	NCT07615413
Lead Sponsor	Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions	KRAS G12C Mutation Advanced Solid Tumor
Enrollment	636 participants
Start Date	2026-06-30
Primary Completion	2029-06-30 (estimated)
Study Completion	2029-12-30 (estimated)
Updated on ClinicalTrials.gov	2026-05-29